With this latest release of Genedata Selector, we again show our commitment to develop our products in close collaboration with our partners and deliver on their key requirements to make them more efficient and successful.
BASEL, Switzerland (PRWEB) November 28, 2017
Genedata, a leading provider of advanced software solutions for R&D, today announced the global release of Genedata Selector 5, the latest version of its innovative enterprise software solution for genome management and analysis. The platform delivers sophisticated analysis pipelines and enterprise-wide data management that improve efficiencies in key applications such as CRISPR-based cell line engineering, clone selection, and biosafety assessment. A new intuitive and easy-to-use interface combined with a novel collaboration portal provides researchers with access to a comprehensive, real-time view of project related information and enables them to share results at the click of a button.
With next-generation sequencing technology becoming more ubiquitous in biopharma R&D, but also in areas like strain optimization and microbiome analysis, many challenges arise in keeping in-depth biological knowledge up to date and easily accessible. Furthermore, the actual analysis, integration, and interpretation of genomic data together with phenotypic information presents another hurdle. A sophisticated software platform is needed to automate complex integration and data analytical tasks and to present results in such a manner that they are easily interpretable by both scientists and project managers. There is where Genedata Selector is making an impact.
Genedata Selector 5 has been developed in close collaborations with key opinion leaders in biopharma, industrial biotech, agribusiness, and consumer health to streamline and automate their experimental data analysis processes. Working closely with user experience and interface experts, Genedata Selector now provides a brand new web-based user interface plus new key functionalities:
- Robust APIs and a rich bioinformatics toolbox that enable data scientists to integrate additional data sources and perform complex integrative data analyses.
- Automated workflows that improve reproducibility and traceability while system transactions are maintained with timestamps to allow for IP generation and compliance.
- Community annotations that enable users to easily associate phenotypic information with specific content or genomic regions.
With this latest release, Genedata Selector also provides an interactive collaboration portal where users can send and receive notifications enabling 1-click access to critical content. Furthermore, users can share interactive views of annotated genomes, expression profiles, and CRISPR related data with members of their project team all without ever leaving the software, making emailing excel sheets and static screenshots obsolete. This also provides a level of transparency to data analysis and management across an enterprise minimizing the duplication of work.
“With this latest release of Genedata Selector, we again show our commitment to develop our products in close collaboration with our partners and deliver on their key requirements to make them more efficient and successful,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Selector we remain focused on streamlining and automating complex NGS-based applications for the biopharmaceutical and related industries and expand our already rapidly growing customer base.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
Follow Us on LinkedIn
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.